上海凤凰企业（集团）股份有限公司 董事会秘书工作制度 第一章总则 第一条 为完善上海凤凰企业（集团）股份有限公司（以下简称公司）治理， 规范公司董事会秘书的选任、履职、培训和考核工作，根据《中华人民共和国公 司法》《中华人民共和国证券法》《上海证券交易所股票上市规则（2025 年 4 月 修订版）》 （以下简称《股票上市规则》） 《上海证券交易所上市公司自律监管指引 第 1 号--规范运作》等法律、行政法规和规范性文件的要求，以及《上海凤凰企 业（集团）股份有限公司章程》（以下简称公司章程）的相关规定，特制定本制 度。 第二条 公司董事会秘书为公司高级管理人员，承担法律、行政法规及公司 章程对董事会秘书所要求的义务，享有相应的工作职权。公司董事会秘书对公司 和董事会负责，应忠实、勤勉地履行职责。 第三条 董事会秘书是公司与上海证券交易所之间的指定联络人。上海证券 交易所仅接受董事会秘书或代行董事会秘书职责的人员以公司名义办理信息披 露、公司治理、股权管理等其相关职责范围内的事务。 第二章任职资格及任免程序 第四条 公司董事会秘书由董事长提名，董事会聘任和解聘。公司董事会秘 书与董事会任期一致，可以连续聘任。 ...

（2025年修订） 第一章 总则 第一条 为进一步完善北京北陆药业股份有限公司（以下简称"公司"）治理结构，规 范公司总经理的工作，依照《中华人民共和国公司法》 （以下简称"《公司法》"）、 《深圳证券 交易所创业板股票上市规则》和《北京北陆药业股份有限公司章程》（以下简称"《公司章 程》"）以及国家的相关法规，特制定本细则。 第二条 公司依法设置总经理。总经理主持公司日常生产经营和管理工作，组织实施 董事会决议，对董事会负责。 第二章 总经理的任职资格与任免程序 第三条 总经理任职应当具备下列条件： （四）诚信勤勉，廉洁奉公，民主公道； （五）年富力强，有较强的使命感和积极开拓进取精神。 （一）具有较丰富的经济理论知识、管理知识及实践经验，具有较强的经营管理能力； （二）具有调动员工积极性的领导能力，建立合理的组织机构、协调各种内外关系和 统揽全局的能力； （三）具有一定年限的企业管理或经济工作经历，精通本行，熟悉多种行业的生产经 营业务和掌握国家有关政策、法律、法规； 第四条 有下列情形之一者，不得担任公司总经理： （一）无民事行为能力或者限制民事行为能力者； （二）因贪污、贿赂、侵占财产、挪用财产罪或者 ...

汇中仪表股份有限公司 汇中仪表股份有限公司 董事会审计委员会年度财务报告审议工作规程 第一条 为完善公司治理结构，进一步加强公司内部控制建设，充分发挥 董事会审计委员会对公司年度财务报告的监督作用，根据相关规定，特制订本 规程。 第二条 董事会审计委员会委员在公司年度财务报告编制过程中，应参照 中国证监会、公司注册地的证券监督管理机构和深圳证券交易所的相关规定及 《汇中仪表股份有限公司章程》（以下简称"《公司章程》"）赋予的职责， 董事会审计委员会年度财务报告审议工作规程 第一章 总 则 勤勉尽责地开展工作，保证公司年报的真实、准确、完整和及时。 第三条 审计委员会委员应认真学习中国证监会、深圳证券交易所及其他 主管部门关于年报的规定和要求，积极参加其组织的培训。 第二章 年度财务报告审核和沟通机制 第四条 公司年度财务报告审计工作的时间安排应根据相关监管要求和董 事会的年度工作计划，由董事会审计委员会与负责公司年度审计工作的会计师 事务所（以下简称"年审会计师事务所"）协商确定。 第五条 董事会审计委员会应在为公司提供年度审计的会计师（以下简称 "年审会计师"）进场前审阅公司编制的财务会计报表，形成书面意见 ...

第四条 独立董事因故不能出席专门会议的，可以书面委托其他独立董事代 为出席。 汇中仪表股份有限公司 独立董事专门会议工作制度 汇中仪表股份有限公司 独立董事专门会议工作制度 第一章 总则 第一条 汇中仪表股份有限公司（以下简称"公司"）为进一步完善法人治 理结构，规范公司运作，充分发挥公司独立董事作用，根据《中华人民共和国公 司法》《上市公司独立董事管理办法》《深圳证券交易所上市公司自律监管指引 第 2 号—创业板上市公司规范运作》等有关法律法规、规范性文件及《汇中仪表 股份有限公司章程》（以下简称"《公司章程》"）的有关规定，制定本工作制 度。 第二章 会议规则 第二条 独立董事专门会议（以下简称"专门会议"）全部由公司独立董事 参加。专门会议应当由过半数独立董事共同推举 1 名独立董事召集和主持；召集 人不履职或者不能履职时，2 名及以上独立董事可以自行召集并推举 1 名代表主 持。 第三条 独立董事应当定期或者不定期召开专门会议，至少每一年召开 1 次 定期会议。定期会议应于会议召开前 5 日通知全体独立董事，临时会议应于会议 召开前 3 日通知全体独立董事。 因情况紧急，需要尽快召开临时会议的，可以通 ...

（2025年修订） 第一章 总 则 （五）个人所负数额较大的债务到期未清偿被人民法院列为失信被执行人； （六）最近三十六个月内受到中国证监会行政处罚； （七）最近三十六个月内受到证券交易所公开谴责或三次以上通报批评； 第二条 公司董事会对股东会负责，并依据国家有关法律、法规和《公司章程》行使职 权。 第二章 董事的资格及任职 第三条 公司董事为自然人，有下列情形之一的，不能担任公司的董事，其中独立董事 的任职资格另有规定的，从其规定。 （一）无民事行为能力或者限制民事行为能力； （二）因贪污、贿赂、侵占财产、挪用财产或者破坏社会主义市场经济秩序，被判处刑 罚，或者因犯罪被剥夺政治权利，执行期满未逾五年，被宣告缓刑的，自缓刑考验期满之 日起未逾二年； 第一条 为规范北京北陆药业股份有限公司（以下简称"公司"）董事会的工作秩序和 行为方式，保证公司董事会依法行使权利、履行职责、承担义务，根据《中华人民共和国公 司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、 中国证券监督管理委员会（以下简称"中国证监会"）颁布的《上市公司治理准则》（以下 简称"《治理准则》"）、《深圳证券交 ...

（2025年修订） 第三条 本工作制度所称的高级管理人员是指公司的总经理、常务副总经理、副总经 理、首席运营官、财务负责人、董事会秘书。 第二章 人员组成 第四条 提名委员会成员由三名董事组成，其中独立董事两名。 第五条 提名委员会委员由董事长、二分之一以上独立董事或者全体董事三分之一以 上提名，由董事会选举产生。 第六条 提名委员会设主任委员一名，负责主持委员会工作。主任委员由独立董事委 员担任，并经全体委员过半数选举产生。 第七条 提名委员会任期与董事会一致，委员任期届满，可以连选连任。期间如有委 员不再担任公司董事职务，自动失去委员资格，并由董事会根据上述第四至第六条规定补 足委员人数。 第一章 总则 第一条 为规范北京北陆药业股份有限公司（以下简称"公司"）董事和高级管理人 员的产生，优化董事会组成，进一步完善公司治理结构，根据《中华人民共和国公司法》、 《上市公司治理准则》、《北京北陆药业股份有限公司章程》（以下简称"《公司章程》"） 及其他有关规定，公司董事会特设立提名委员会（以下简称"提名委员会"），并制定本工 作制度。 第二条 提名委员会是董事会设立的专门工作机构，主要负责对公司董事和高级管理 ...

Core Viewpoint - The ongoing power struggle between Shandong Jiabao Group and Jinan Weierkang Industrial Group has drawn significant attention, highlighting the complexities of corporate governance and the competitive dynamics between the two companies [1] Group 1: Company Overview - Jiabao Group is a leading player in the dairy industry in China, with a revenue exceeding 8 billion yuan in 2023, and operates three large-scale modern dairy farms with a total of 50,000 dairy cows [2] - Weierkang Group, recognized as a national backbone cold chain logistics base, reported a revenue of 12 billion yuan in 2023 and has a daily processing capacity of over 8,000 tons of fresh products [2][9] Group 2: Shareholding Structure - Jiabao Group holds 100% of Weierkang Group, but the shareholding structure is complex, with various stakeholders including labor unions holding significant stakes, such as the Weierkang Group labor union with 12.33% [4] - The intricate shareholding structure creates potential conflicts in decision-making and interest representation, complicating the governance of both companies [4] Group 3: Legal and Governance Issues - A recent shareholders' meeting of Jiabao Group led to decisions that intensified the conflict, including the appointment of Jiabao's chairman as Weierkang's chairman, which was contested by Weierkang's labor union due to alleged procedural flaws [5][6] - The ongoing litigation has resulted in frozen shares, halting the auditing and dividend distribution processes for 2024, which negatively impacts shareholder interests [7][8] Group 4: Business Impact - The internal conflict has led to business stagnation for Weierkang, with management instability causing significant operational disruptions and eroding market confidence [7][8] - The dispute has escalated from procedural disagreements to direct confrontations over control and daily operations, with both companies leveraging their respective strengths in the dairy and cold chain sectors [9]

Group 1 - The company held its first meeting of the 10th Board of Directors on May 22, 2025, with all 9 directors present, confirming the legality and validity of the meeting [1] - The board elected Mr. Wu Jianhui as the Chairman of the 10th Board of Directors, with a term lasting until the end of the board's term [2] - The board elected Mr. Xiao Yao as the Vice Chairman, also with a term until the end of the board's term [2] Group 2 - The board approved the election of various committee members for the 10th Board of Directors, ensuring that independent directors hold a majority in the Audit and Compensation Committees [2][3] - Mr. Xiao Yao was appointed as the President of the company, with a term until the end of the board's term [3][4] - The board approved the appointment of other senior management personnel, including Mr. Li Jianchang as Executive Vice President and Ms. Zhang Liping as Chief Financial Officer, all with terms until the end of the board's term [4] Group 3 - The board appointed Mr. Li Ruixue as the Secretary of the Board, with a term until the end of the board's term [5] - The board appointed Ms. Chen Zhe as the Securities Affairs Representative, also with a term until the end of the board's term [5] - The board approved revisions and additions to certain internal regulations to enhance corporate governance [6][7] Group 4 - The company adjusted its organizational structure by integrating overlapping departments and optimizing functions, resulting in the elimination of several departments and the establishment of new ones [7] - The board authorized the management to implement the organizational adjustments and subsequent optimizations [7]

Group 1: Company Strategy and Performance - The company aims to maintain competitiveness by implementing strategies that align with national policies, focusing on "serving the real economy, wealth management, and major strategic initiatives in Hubei" [1] - The annual profit distribution plan includes a cash dividend of 1.50 CNY per 10 shares, approved by the board and shareholders [1] - The company reported a net asset value of 7.09 CNY at the end of 2024 and 7.26 CNY at the end of March 2025 [3] Group 2: Risk Management and Governance - The company emphasizes effective risk management and internal controls as essential for stable operations, establishing a comprehensive risk management system [3] - The governance structure promotes a separation of powers among the shareholders, board, supervisors, and management, ensuring transparency and accountability [2] - The company has received an "A" rating for 14 consecutive years in the Shenzhen Stock Exchange's annual information disclosure assessment [2] Group 3: Market and Regulatory Environment - The company is adapting to the "Action Plan for Promoting High-Quality Development of Public Funds," which aims to enhance the research business and income models [5] - The company plans to leverage policy opportunities to expand its mergers and acquisitions business, enhancing its industry integration capabilities [6] - The company is currently undergoing a major shareholder change, with the application accepted by the China Securities Regulatory Commission [8] Group 4: Shareholder Value and Communication - The company has maintained a stable cash dividend policy for 17 consecutive years, with a high dividend payout ratio among listed brokers [6] - The company is committed to improving information disclosure quality and investor relations management to enhance shareholder value [6] - The company acknowledges that stock price fluctuations are influenced by various external factors and emphasizes the importance of investment risk awareness [6]

Core Points - The company has prepared the 2024 annual report, which has been approved by the board and is submitted for shareholder review [1] - The 2024 board work report emphasizes the board's role in strategy formulation, decision-making, and risk prevention, highlighting governance improvements and future work plans [2] - The company aims to enhance its governance structure and operational efficiency while focusing on strategic development and risk management [4][6] Group 1: Annual Reports and Proposals - The 2024 annual report has been compiled and approved, awaiting shareholder meeting review [1] - The board's work report outlines strategic governance improvements and future objectives for 2025 [2] - The independent directors' report for 2024 has been approved and is also submitted for shareholder review [29] Group 2: Governance and Risk Management - The board emphasizes the integration of party leadership and corporate governance, enhancing the governance framework [4] - The company has implemented a comprehensive risk management system, focusing on major risk assessments and preventive measures [15] - The board has conducted extensive evaluations of significant risks, ensuring effective monitoring and control [15] Group 3: Financial Performance and Strategic Initiatives - The company reported a 9.75% increase in new contracts and a 7.56% rise in revenue year-on-year [10] - The board is committed to advancing strategic initiatives, including significant energy projects and technological innovations [10][11] - The company has allocated 139.82 billion yuan for R&D, achieving notable advancements in technology and innovation [10] Group 4: Shareholder Engagement and Market Value - The company has introduced a mid-term dividend plan, increasing the cash dividend ratio by 30% compared to the previous year [23] - The board has actively engaged with investors, conducting multiple roadshows and enhancing communication channels [26] - The company has received various accolades for its governance and market performance, reflecting its commitment to quality and transparency [27] Group 5: Future Work Plans - The board plans to enhance the governance structure and improve the efficiency of subsidiary boards [28] - The company aims to strengthen its market value management and investor relations strategies [28] - Future initiatives will focus on optimizing governance systems and ensuring compliance with regulatory requirements [28]